Vancouver, British Columbia – June 20, 2012 – Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today results from a preclinical study of its sodium glucose transporter (SGLT) inhibitor in monkeys. When administered orally, Sirona Biochem’s SGLT inhibitor, SBM-TFC-039, triggered glucosuria in a dose-dependent manner. In addition, the glucosuria effect was robust for the full 24 hours studied.
“At the recent American Diabetes Association meeting in Philadelphia, it was apparent that SGLT inhibitors are a potentially ground-breaking treatment for Type 2 diabetes,” said Dr. Howard Verrico, President and CEO of Sirona Biochem. “Preclinical results of our SGLT inhibitor, SBM-TFC-039, in multiple species have consistently demonstrated its efficacy and we are exploring data that may differentiate SBM-TFC-039 from the other SGLT inhibitors in development,” he added.
SBM-TFC-039 is an SGLT inhibitor drug candidate for Type 2 diabetes. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
SBM-TFC-039 has been tested acutely and chronically in a rodent diabetic model, in addition to the latest study in primates. In those tests, SBM-TFC-039 has consistently demonstrated a glucose-lowering effect in a dose-dependent manner.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.